Product Images Topiramate
View Photos of Packaging, Labels & Appearance
- Table 2 - Part 1 - topiramate 25mg tab for glenmark 1
- Table 12 - topiramate 25mg tab for glenmark 10
- Glenmark Logo - topiramate 25mg tab for glenmark 11
- IMAGE LABEL - topiramate 25mg tab for glenmark 12
- Table 2 - Part 2 - topiramate 25mg tab for glenmark 2
- Table 3 - topiramate 25mg tab for glenmark 3
- Table 4 - topiramate 25mg tab for glenmark 4
- Table 5 - topiramate 25mg tab for glenmark 5
- Table 6 - topiramate 25mg tab for glenmark 6
- Table 7 - topiramate 25mg tab for glenmark 7
- Structure of topiramate - topiramate 25mg tab for glenmark 8
- Figure 1 - topiramate 25mg tab for glenmark 9
Product Label Images
The following 12 images provide visual information about the product associated with Topiramate NDC 33261-106 by Aidarex Pharmaceuticals Llc, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
Table 2 - Part 1 - topiramate 25mg tab for glenmark 1

This appears to be a table with information on adverse reactions to different dosages of Tobiramate (an medication), based on a sample of 160 people taking 50mg/daily and 159 people taking 400mg/daily. Adverse reactions are categorized by body system and specific disorders. Some examples of adverse reactions and their frequency include: asthenia (6 at 50mg, 3 at 400mg), leg pain (3 at 50mg), weight decrease (14 at 400mg), dry mouth (2 at 50mg), and increased Gamma-GT levels in the liver (6 at 400mg).*
Table 12 - topiramate 25mg tab for glenmark 10

This is a table of results from studies evaluating the efficacy of Topiramate, a drug used to treat different types of seizures. The table shows the target dosage (in mg/day) of Topiramate and the corresponding results in terms of median percentage reduction in seizures and percentage of responders (subjects showing improvement). The studies were conducted in adults and pediatric patients with different types of seizures, including partial onset seizures, primary generalized tonic-clonic seizures, and Lennox-Gastaut syndrome. The results are compared with a placebo and show that Topiramate is effective in reducing seizure frequency and severity, with some differences observed depending on the type of seizure and patient group.*
IMAGE LABEL - topiramate 25mg tab for glenmark 12

This is a description of a medicine called Topiramate, which is manufactured by Aidarex Pharmaceuticals LLC. It comes in a white round tablet form that is film-coated and has "25" on one side and "G" on the other. Each bottle contains 90 tabs and is a generic form of TOPAMAX. The medicine is to be stored at controlled room temperature and taken as prescribed by a doctor. The prescription is only available in the United States and cannot be sold to children. The NDC number is 83261-0106-00. The manufacturer is Glenmark Generics LTD. from India. There are several instances of duplicate text lines.*
Table 2 - Part 2 - topiramate 25mg tab for glenmark 2

This is a list of adverse reactions reported by patients during a study. The reactions include various psychiatric disorders such as depression, anxiety, and difficulty concentrating, as well as physical symptoms such as anemia, infections, respiratory issues, skin problems, and urinary disorders. The percentage of patients reporting each reaction is included.*
Table 3 - topiramate 25mg tab for glenmark 3

This is a table detailing Adverse Reactions on a bio-medicine study. It reports the number of patients that experienced each adverse event and the respective percentage. The reactions are separated into different category for each body system or disorder type. Some of the events include fever, diarrhea, weight decrease, respiratory tract infections, among others. Patients could be included in more than one adverse event category.*
Table 4 - topiramate 25mg tab for glenmark 4

This is a table showing different adverse reactions and their frequency in patients taking different dosages of topiramate. The reactions are listed according to the body system affected, such as general, nervous, gastrointestinal, respiratory, and reproductive disorders. The number of patients experiencing each reaction is shown for each dosage group. The reactions reported are those experienced by at least 19% of patients in the topiramate group and more frequently than in the placebo group.*
Table 5 - topiramate 25mg tab for glenmark 5

This is a chart displaying the adverse reactions reported by patients taking Topiramate Dosage of 200mg/day. The adverse reactions are listed according to body system and include fatigue, chest pain, hypertension, paresthesia, dizziness, tremor, leg cramps, language problems, among others. The values indicate the percentage of patients that reported the given adverse reaction during the study. Patients may have reported more than one adverse reaction and can be included in more than one category. The chart also includes a disclaimer that these were add-on/adjunctive trials where patients were receiving concomitant antiepileptic drugs in addition to topiramate or placebo.*
Table 6 - topiramate 25mg tab for glenmark 6

This is a table that shows the adverse reactions caused by different doses of Topiramate (placebo, 200mg/day, 400mg/day, and 600-1000mg/day). The adverse reactions mentioned include fatigue, nervousness, difficulty with concentration/attention, confusion, depression, anorexia, language problems, anxiety, mood problems, and weight decrease. It is also noted that dose-response studies were not conducted for other adult indications or for pediatric indications.*
Table 7 - topiramate 25mg tab for glenmark 7

This text appears to be a list of adverse reactions and their frequency for patients taking Topiramate and Placebo respectively. The reactions are categorized by body system and include fatigue, injury, allergic reactions, neurological disorders, gastrointestinal disorders, psychiatric disorders, respiratory disorders, and urinary system disorders, among others. The percentage of patients reporting each reaction is given. It is suggested that patients were also taking other antiepileptic drugs in addition to Topiramate or placebo.*
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.